Composition for relieving individual dysphoria, crying and screaming and / or flatulence and application thereof

Abstract

The invention provides a composition for relieving individual dysphoria, cry and / or flatulence and application thereof, the composition comprises breast milk oligosaccharide, 1, 3-dioleoyl-2-palmitic acid triglyceride, lactoferrin, galactooligosaccharide and fructo-oligosaccharide, the breast milk oligosaccharide, the 1, 3-dioleoyl-2-palmitic acid triglyceride, the lactoferrin, the galactooligosaccharide, the fructo-oligosaccharide, the 1, 3-dioleoyl-2-palmitic acid triglyceride, the lactoferrin, the galactooligosaccharide, the fructo-oligosaccharide and the 1, the weight ratio of the 1, 3-dioleic acid-2-palmitic acid triglyceride to the lactoferrin to the galactooligosaccharide to the fructo-oligosaccharide is (0.85 to 2.95) to (5 to 16) to (0.05 to 0.7) to (1 to 3) to (0.25 to 1.1); wherein the breast milk oligosaccharide comprises 2 '-fucosyllactose and lactose-N-neotetraose. The composition can reduce dysphoria and crying, relieve flatulence and provide digestion protection closer to breast milk for infants who cannot be fed with pure breast milk or are insufficient in breast milk.

Description

Technical Field

[0001] This invention relates to the field of dairy technology, and more specifically to a composition that can be used to relieve individual irritability, crying and / or bloating, and its application. Background Technology

[0002] In the early stages of infant development, irritability, crying, and gas are frequent feeding problems faced by parents. These issues are often related to the immaturity of infants' digestive systems and their susceptibility to external stimuli. Infants aged 0-6 months have not yet established a stable gut microbiota, and their digestive enzyme secretion is insufficient. Their ability to digest food (especially certain components in formula) is weak, easily leading to excessive gas production from food fermentation in the intestines, causing bloating and abdominal discomfort. Since infants cannot express their feelings verbally, they can only communicate through persistent crying, fidgeting, and kicking. This not only affects their emotional state and sleep quality but also significantly increases the caregiver's stress and anxiety. Therefore, addressing infant abdominal discomfort and reducing irritability and crying through scientifically balanced nutrition, focusing on gut health and digestive function, has become an important direction in the development of infant formula and scientific feeding guidance. Summary of the Invention

[0003] One object of the present invention is to provide a composition that can be used to relieve individual irritability, crying and / or bloating.

[0004] Another object of the present invention is to provide a food comprising the above-described composition.

[0005] Another object of the present invention is to provide the use of the above-described composition or the above-described food in the preparation of products for relieving individual irritability, crying and / or bloating.

[0006] This invention discovers that the naturally occurring active ingredients and functional prebiotics in breast milk are key to maintaining infant gut health and reducing discomfort symptoms. Specifically, the synergistic combination of human milk oligosaccharides (HMOs), 1,3-dioleoyl-20 palmitate triglycerides (OPO structured lipids), galactooligosaccharides (GOS), and fructooligosaccharides (FOS) can improve the infant gut environment from multiple dimensions, reduce the digestive burden, directly relieve bloating, and reduce irritability and crying caused by abdominal discomfort, providing infants in non-exclusively breastfed environments with a more breast-like "comfort protection."

[0007] Specifically, on the one hand, the present invention provides a composition that can be used to relieve individual irritability, crying, and / or bloating, the composition comprising human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol triglyceride, lactoferrin, galactooligosaccharides, and fructooligosaccharides, wherein the weight ratio of human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol triglyceride, lactoferrin, galactooligosaccharides, and fructooligosaccharides is (0.85-2.95):(5-16):(0.05-0.7):(1-3):(0.25-1.1); The human milk oligosaccharides include 2'-fucosylated lactose and lactose-N-neotetrasaccharide.

[0008] In the above composition, preferably, the weight ratio of 2'-fucosylated lactose to lactose-N-neotetrasaccharide is (0.7-2.5):(0.15-0.45).

[0009] According to a specific embodiment of the present invention, the weight ratio of 2'-fucosylated lactose, lactose-N-neotetrasaccharide, 1,3-dioleoyl-2-palmitoylglycerol triglyceride, lactoferrin galactooligosaccharide and fructooligosaccharide is 0.935:0.195:8.6:0.1:1.245:0.625.

[0010] On the other hand, the present invention also provides a food product comprising human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol triglyceride, lactoferrin, galactooligosaccharides, and fructooligosaccharides, wherein the weight ratio of human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol triglyceride, lactoferrin, galactooligosaccharides, and fructooligosaccharides is (0.85-2.95):(5-16):(0.05-0.7):(1-3):(0.25-1.1). The human milk oligosaccharide includes 2'-fucosylated lactose and lactose-N-neotetrasaccharide, and the weight ratio of 2'-fucosylated lactose and lactose-N-neotetrasaccharide is (0.7-2.5):(0.15-0.45).

[0011] In the aforementioned food products, preferably, the weight ratio of 2'-fucosylated lactose, lactose-N-neotetrasaccharide, 1,3-dioleoyl-2-palmitoylglycerol triglyceride, lactoferrin galactooligosaccharide, and fructooligosaccharide is 0.935:0.195:8.6:0.1:1.245:0.625.

[0012] On the other hand, the present invention also provides the use of the above-described composition or the above-described food in the preparation of products that relieve individual irritability, crying and / or bloating.

[0013] According to a specific embodiment of the present invention, the composition for relieving individual irritability, crying, and / or bloating is a food product; Preferably, the individual is an infant or young child.

[0014] According to a specific embodiment of the present invention, the food includes nutritional supplements, liquid milk, non-infant milk powder, infant formula, or complementary food for infants.

[0015] According to a specific embodiment of the present invention, the amount of lactoferrin used in the product is 50-700 mg / 100g powder in non-infant milk powder or infant formula powder, or 0.065-0.91g / L when converted to milk liquid, preferably 100 mg / 100g powder (0.13 g / L when converted to milk liquid).

[0016] According to a specific embodiment of the present invention, the application amount of 2'-fucosylated lactose in the product is: 700-2500 mg / 100g powder in non-infant milk powder or infant formula, or 0.91-3.25 g / L in milk equivalent, preferably 935 mg / 100g powder (1.2155 g / L in milk equivalent); the application amount of lactose-N-neotetrasaccharide in food is: 150-450 mg / 100g powder in non-infant milk powder or infant formula, or 0.195-0.585 g / L in milk equivalent, preferably 195 mg / 100g powder (0.2535 g / L in milk equivalent).

[0017] According to a specific embodiment of the present invention, the application amount of the 1,3-dioleoyl-2-palmitoylglycerol in the product is: 5-16 g / 100 g powder in non-infant milk powder or infant formula powder, or 6.5-20.8 g / L when converted to milk liquid, preferably 8.6 g / 100 g powder (equivalent to 11.18 g / L when converted to milk liquid).

[0018] According to a specific embodiment of the present invention, the amount of galactooligosaccharide used in the product is 1-3 g / 100 g powder in non-infant milk powder or infant formula powder, or 1.3-3.9 g / L when converted to milk liquid, preferably 1.245 g / 100 g powder (equivalent to 1.6185 g / L when converted to milk liquid).

[0019] According to a specific embodiment of the present invention, the amount of galactooligosaccharide used in the product is 0.25-1.1 g / 100g powder in non-infant milk powder or infant formula powder, or 0.325-1.43 g / L when converted to milk liquid, preferably 0.625 g / 100g powder (0.8125 g / L when converted to milk liquid).

[0020] In this invention, the non-infant can be a child or an adult.

[0021] The present invention has the following beneficial technical effects: The combination of human milk oligosaccharides, OPO, lactoferrin, GOS and FOS can reduce infant irritability and crying, and relieve gas. It provides digestive protection that is closer to breast milk for infants who cannot be exclusively breastfed or whose breast milk is insufficient, and also provides parents with a scientific nutritional support solution to solve feeding problems.

[0022] Human milk oligosaccharides (HMOs) build a "healthy defense line" for the gut. HMOs are not directly digested and absorbed by infants and young children; instead, they serve as "exclusive food" for beneficial bacteria in the gut (such as Bifidobacteria), selectively promoting their proliferation and quickly helping infants and young children establish a stable gut microbiota balance. Simultaneously, HMOs can form a protective film on the intestinal mucosa, reducing the colonization of harmful bacteria (such as gas-producing bacteria and pathogens) on the intestinal wall, lowering the risk of intestinal inflammation and abnormal fermentation, and fundamentally reducing gas production and relieving bloating. Furthermore, some HMOs can regulate intestinal nerve sensitivity, alleviating abdominal discomfort and indirectly reducing irritability and crying in infants and young children caused by pain.

[0023] OPO structured lipids can reduce the digestive burden and intestinal irritation. Traditional formula milk powder fats often have a structure where palmitic acid is located at positions 1 and 3, easily combining with calcium in the infant's intestines to form insoluble calcium soaps. Calcium soaps not only affect calcium absorption but can also irritate the intestinal mucosa, leading to disordered intestinal motility, increased food retention and gas accumulation, causing bloating, constipation, and abdominal discomfort. OPO structured lipids, mimicking the natural structure of fats in breast milk (palmitic acid mainly located at position 2), are more easily broken down and absorbed by infants' digestive enzymes, significantly reducing calcium soap formation and lowering the digestive burden on the intestines. Simultaneously, it can promote the absorption efficiency of fats and fat-soluble vitamins, reduce the fermentation and gas production of undigested food in the intestines, and directly relieve discomfort caused by bloating.

[0024] GOS and FOS, as dual prebiotics, are a classic prebiotic combination for strengthening gut function. GOS has a shorter molecular chain, allowing for rapid utilization by beneficial bacteria in the upper gut, quickly regulating the gut microbiota balance. FOS has a longer molecular chain, reaching the lower gut to exert its effects, continuously promoting the proliferation of beneficial bacteria. Working together, beneficial bacteria ferment and produce short-chain fatty acids (such as acetic acid and butyric acid). These substances provide energy to intestinal epithelial cells, enhancing the intestinal barrier function, and regulating intestinal peristalsis, accelerating the expulsion of gas and waste, effectively relieving bloating. Simultaneously, a stable gut environment reduces the impact of intestinal discomfort on infants' emotions, thereby decreasing the frequency of irritability and crying. Attached Figure Description

[0025] Figure 1 The average number of times of agitation was recorded for each group.

[0026] Figure 2 Statistics on the average crying time for each group.

[0027] Figure 3 The average number of bloating episodes for each group was statistically analyzed. Detailed Implementation

[0028] In order to provide a clearer understanding of the technical features, objectives and beneficial effects of the present invention, the technical solution of the present invention will now be described in detail below, but it should not be construed as limiting the scope of implementation of the present invention.

[0029] Example: This study investigated the effects of a combination of human milk oligosaccharides (HMOs), OPO, lactoferrin, GOS, and FOS in infant formula on infant irritability, crying, and gas. The study included an experimental group, a control group, and a breast milk group. A total of 300 infants aged 14 days or younger were recruited, of whom 255 completed the intervention. Infants were divided into three groups based on the formula they were fed: the experimental group (NTotal=84) with HMOs, OPO, lactoferrin, GOS, and FOS added to their infant formula; the control group (NTotal=90) with GOS added only to their infant formula; and the breast milk group (NTotal=81). Questionnaires were completed by parents in each group to collect data on the infants' baseline, 6-week, 3-month, 4-month, and 6-month ages regarding irritability, crying, and gas. The specific ingredients of each group's formula are shown in Table 1. Table 1

[0030] Data Results: Statistics on the average number of times of irritability in each group are as follows: Figure 1 As shown in Tables 2-4, the specific statistical results of irritability in infants and young children in each group are shown in Tables 3-4 (Tables 3 and 4 are continuations of Table 2). The statistics mainly include the average number of times infants and young children become irritable in the examples, whether irritability occurs at least once a day, whether irritability occurs frequently, whether irritability occurs ≥1 time in 3 days, and whether irritability occurs ≥2 times / day on 2 days in 3 days.

[0031] Table 2

[0032] Table 3

[0033] Table 4 This indicates a significant difference compared to the experimental group (p < 0.05).

[0034] Statistical analysis of parental reports on infant irritability revealed no statistically significant differences in irritability among all infants at baseline, indicating comparability. The experimental group showed significantly fewer average irritability episodes at 6 weeks, 3 months, 4 months, and 6 months of age compared to the control group, but no statistically significant difference compared to the breastfed group. Regarding the frequency of irritability and whether irritability occurred ≥1 times within 3 days, infants in the experimental group showed significantly fewer episodes at 6 weeks, 3 months, 4 months, and 6 months of age compared to the control group, but no statistically significant difference compared to the breastfed group. For the criteria of at least one episode of irritability per day and whether irritability occurred ≥2 times / day on 2 days within 3 days, infants at 6 months of age showed significant differences compared to the control group, but no difference compared to the breastfed group; no significant differences were found among the three groups at other observation points.

[0035] Clinical trials on infants have demonstrated that a combination of human milk oligosaccharides, OPO, GOS, and FOS can reduce irritability in infants and young children.

[0036] The average crying time for each group is as follows: Figure 2 As shown in Table 5, the specific statistical results of infant crying in each group are presented. The main statistical data included the average crying time of the infants in the example and whether crying occurred at least once a day to assess the frequency of crying.

[0037] Table 5 This indicates a significant difference compared to the experimental group (p < 0.05).

[0038] Statistical analysis of parental reports on infant crying revealed no statistically significant differences in crying levels among all infants at baseline, indicating comparability. The average crying duration in the experimental group was significantly shorter than that in the control group at 6 weeks, 3 months, 4 months, and 6 months of age, but not statistically different from the breastfed group. The same results were observed for the indicator of crying at least once a day. This clinical trial in infants confirms that a combination of human milk oligosaccharides, OPO, GOS, and FOS can reduce crying in infants and young children.

[0039] The average number of bloating episodes in each group is as follows: Figure 3 As shown in Tables 6 and 7, the specific statistical results of gas occurrence in infants and young children in each group are shown in Table 7 (Table 7 is a continuation of Table 6). The main statistical data were collected on the average number of gas episodes in the infants and young children in the examples, whether gas occurred at least once a day, whether gas occurred frequently, whether gas occurred ≥1 time within 3 days, and whether gas occurred ≥2 times / day on 2 days within 3 days.

[0040] Table 6

[0041] Table 7 This indicates a significant difference compared to the experimental group (p < 0.05).

[0042] Statistical analysis of parental reports on gas levels revealed no statistically significant differences in gas levels among all infants at baseline, indicating comparability. The experimental group showed significantly fewer average gas episodes at 6 weeks, 3 months, 4 months, and 6 months of age compared to the control group, but no statistically significant difference compared to the breastfed group. The same results were observed for indicators such as whether gas occurred at least once daily, the frequency of gas, whether gas occurred ≥1 time within 3 days, and whether gas occurred ≥2 times / day on 2 days within 3 days; all showed significantly lower rates at 6 weeks, 3 months, 4 months, and 6 months of age compared to the control group, but no statistically significant difference compared to the breastfed group.

[0043] Clinical trials on infants have demonstrated that a combination of human milk oligosaccharides, OPO, GOS, and FOS can reduce the occurrence of gas in infants and young children.

Claims

1. A composition for relieving individual irritability, crying, and / or gas, the composition comprising human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol, lactoferrin, galactooligosaccharides, and fructooligosaccharides, wherein the weight ratio of human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol, lactoferrin, galactooligosaccharides, and fructooligosaccharides is (0.85-2.95):(5-16):(0.05-0.7):(1-3):(0.25-1.1); in, The human milk oligosaccharides include 2'-fucosylated lactose and lactose-N-neotetrasaccharide.

2. The composition according to claim 1, wherein, The weight ratio of 2'-fucosylated lactose to lactose-N-neotetrasaccharide is (0.7-2.5):(0.15-0.45).

3. A food product comprising human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol, lactoferrin, galactooligosaccharides, and fructooligosaccharides, wherein the weight ratio of human milk oligosaccharides, 1,3-dioleoyl-2-palmitoylglycerol, lactoferrin, galactooligosaccharides, and fructooligosaccharides is (0.85-2.95):(5-16):(0.05-0.7):(1-3):(0.25-1.1). in, The human milk oligosaccharides include 2'-fucosylated lactose and lactose-N-neotetrasaccharide; Preferably, the weight ratio of 2'-fucosylated lactose to lactose-N-neotetrasaccharide is (0.7-2.5):(0.15-0.45).

4. The use of the composition of claim 1 or 2 or the food product of claim 3 in the preparation of a composition for relieving individual irritability, crying and / or bloating.

5. The application according to claim 4, wherein, The composition for relieving irritability, crying, and / or gas in an individual is a food product; preferably, the individual is an infant or young child. Preferably, the food product includes nutritional supplements, liquid milk, non-infant milk powder, infant formula, or complementary foods for infants and young children.

6. The application according to claim 5, wherein, The application amount of lactoferrin in the product is 50-700 mg / 100g powder in non-infant milk powder or infant formula, or 0.065-0.91g / L when converted to milk liquid.

7. The application according to claim 5, wherein, The application amount of 2'-fucosylated lactose in the product is as follows: 700-2500 mg / 100g powder in non-infant milk powder or infant formula, or 0.91-3.25g / L when converted to milk liquid; the application amount of lactose-N-neotetrasaccharide in food is as follows: 150-450 mg / 100g powder in non-infant milk powder or infant formula, or 0.195-0.585g / L when converted to milk liquid.

8. The application according to claim 5, wherein, The application amount of the 1,3-dioleoyl-2-palmitoylglycerol in the product is 5-16g / 100g powder in non-infant milk powder or infant formula, or 6.5-20.8g / L when converted to milk liquid.

9. The application according to claim 5, wherein, The amount of galactooligosaccharide used in the product is 1-3g / 100g powder in non-infant milk powder or infant formula, or 1.3-3.9g / L when converted to milk liquid.

10. The application according to claim 5, wherein, The amount of galactooligosaccharide used in the product is 0.25-1.1g / 100g powder in non-infant milk powder or infant formula, or 0.325-1.43g / L when converted to milk liquid.

Images